Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...

The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...

His career has included stops at Eli Lilly, Novian Health and, for the last 16 years, Amgen. His tenure at Amgen included roles in sales and marketing for many of its hematology and oncology ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $267.10. Discover ...

A dozen wake Technical Community College students signed letters of intent on Monday to work with Amgen. Amgen is planning a $1 billion expansion in Holly Springs. “This is a really good ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...